Hôpital Henri-Mondor AP-HP

62 currently recruiting clinical trials
Create patient profile for matching
Phase 3 Amyloidosis #NCT06563895 #2024-513547-82-00
Required histologic types
Other
Required genetic anomalies
Other mutation
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required organ involvement status
Absence
Hôpital Henri-Mondor AP-HP (Créteil)
Eidos Therapeutics, a BridgeBio company
Phase 3 Amyloidosis #NCT07052903 #2024-519917-72-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
Hôpital Henri-Mondor AP-HP (Créteil)
Alnylam Pharmaceuticals
Phase 3 Amyloidosis #NCT07223203 #2025-522544-40-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Neurological
Hôpital Henri-Mondor AP-HP (Créteil)
Alnylam Pharmaceuticals
Phase 3 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05198960
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Polycythemia vera Essential thrombocythemia Primary myelofibrosis
Required genetic anomalies
JAK2
Hôpital Henri-Mondor AP-HP (Créteil)
Hôpital Universitaire de Brest
Phase 3 Breast cancer #NCT06966700
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative HR Positive
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Surgery Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC) Radiotherapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Surgery Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC) Radiotherapy Hormone therapy
Hôpital Henri-Mondor AP-HP (Créteil)
Merck Sharp & Dohme LLC
Phase 3 Acute leukemia #NCT07007312 #2025-521314-25-00
Etude de thérapie intensive
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
KMT2A NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
Hôpital Henri-Mondor AP-HP (Créteil)
Kura Oncologie, Inc.
Phase 3 Acute leukemia #NCT07007312 #2025-521314-25-00
Etude de thérapie non intensive
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
Hôpital Henri-Mondor AP-HP (Créteil)
Kura Oncologie, Inc.
Phase 3 Colon cancer Rectal cancer #NCT02885753
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Henri-Mondor AP-HP (Créteil)
Fédération Francophone de Cancérologie Digestive
Phase 3 Colon cancer Rectal cancer #NCT04120701 #2024-515297-27-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive Surgery
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Surgery
Excluded previous treatments at localized stage
Chemotherapy Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Radiotherapy
Hôpital Henri-Mondor AP-HP (Créteil)
CHU Dijon
Phase 3 Colon cancer Rectal cancer #NCT06252649 #2022-502352-31-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
Hôpital Henri-Mondor AP-HP (Créteil)
Amgen